Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
Recruiting
Observational Study
Coronary Artery Disease
Percutaneous Transluminal Coronary Angioplasty
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50,000 (estimated)
- Sponsor
- Seung-Jung Park · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* coronary disease amenable to percutaneous coronary intervention (PCI)
* no clinical and lesion limitations
Exclusion Criteria:
* patients with a mixture of several DES
* terminal illness with life expectancy less than 1 year
* patients with cardiogenic shock
Contacts